What Is Humacyte, Inc. (HUMA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Humacyte, Inc.'s intrinsic value is estimated at $0.40, suggesting the stock is overvalued at its current price of $0.68. With 4 out of 5 models flagging downside (-41.1% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $0.96 (+41.3%), versus Regime Cross at $0.01 (-98.5%). This +139.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About HUMA?
5 of 13 models are currently active for HUMA. Of these, 1 model suggests upside while 4 models suggest overvaluation. The Bayesian DCF estimates HUMA's intrinsic value at $0.27, implying -60.8% downside from the current price. See which stocks rank higher →
How Does HUMA Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, HUMA ranks #121 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Humacyte, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is HUMA a Value Trap?
CirclFi's Value Trap algorithm assigns HUMA a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
5 of 13 models are active for Humacyte, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Humacyte, Inc. is rated at 3.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +139.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every HUMA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across HUMA's 5 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad